Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: Study in vasopressin-deficient Brattleboro rats
Open Access
- 31 August 1999
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (18) , 10397-10402
- https://doi.org/10.1073/pnas.96.18.10397
Abstract
Diabetic nephropathy represents a major complication of diabetes mellitus (DM), and the origin of this complication is poorly understood. Vasopressin (VP), which is elevated in type I and type II DM, has been shown to increase glomerular filtration rate in normal rats and to contribute to progression of chronic renal failure in 5/6 nephrectomized rats. The present study was thus designed to evaluate whether VP contributes to the renal disorders of DM. Renal function was compared in Brattleboro rats with diabetes insipidus (DI) lacking VP and in normal Long-Evans (LE) rats, with or without streptozotocin-induced DM. Blood and urine were collected after 2 and 4 weeks of DM, and creatinine clearance, urinary glucose and albumin excretion, and kidney weight were measured. Plasma glucose increased 3-fold in DM rats of both strains, but glucose excretion was ≈40% lower in DI-DM than in LE-DM, suggesting less intense metabolic disorders. Creatinine clearance increased significantly in LE-DM (P < 0.01) but failed to increase in DI-DM. Urinary albumin excretion more than doubled in LE-DM but rose by only 34% in DI-DM rats (P < 0.05). Kidney hypertrophy was also less intense in DI-DM than in LE-DM (P < 0.001). These results suggest that VP plays a critical role in diabetic hyperfiltration and albuminuria induced by DM. This hormone thus seems to be an additional risk factor for diabetic nephropathy and, thus, a potential target for prevention and/or therapeutic intervention.Keywords
This publication has 52 references indexed in Scilit:
- Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.Journal of Clinical Investigation, 1996
- Characterization of a Novel, Linear Radioiodinated Vasopressin Antagonist: An Excellent Radioligand for Vasopressin V1a ReceptorsNeuroendocrinology, 1995
- Binding of (3H) SR 49059, a Potent Nonpeptide Vasopressin V1a Antagonist, to Rat and Human Liver MembranesBiochemical and Biophysical Research Communications, 1994
- Influence of the level of hydration on the renal response to a protein mealKidney International, 1992
- The effectiveness of arginine vasopressin and sodium salicylate as antipyretics in the Brattleboro ratBrain Research, 1990
- Hormonal regulation of the tricarboxylic acid cycle in the isolated perfused rat liverEuropean Journal of Biochemistry, 1986
- THE EFFECT OF VASOPRESSIN INFUSION ON GLUCOSE METABOLISM IN MANClinical Endocrinology, 1985
- Vasopressin promotes the metabolism of near-physiological concentration of glutamine in isolated rat liver cellsBioscience Reports, 1984
- Convulsive and hypothermic effects of vasopressin in the brain of the ratCanadian Journal of Physiology and Pharmacology, 1980
- Hepatic action of vasopressin: Lack of a role for adenosine‐3′,5′‐cyclic monophosphateFEBS Letters, 1974